Ma Fei，MD

Quick facts

Phase 3 pipeline

• Eribulin biweekly regimen · Oncology
  Eribulin is a microtubule dynamics inhibitor that binds to tubulin and disrupts microtubule formation, leading to cancer cell death.
• Eribulin standard regimen · Oncology
  Eribulin is a microtubule dynamics inhibitor that binds to tubulin and suppresses microtubule growth, leading to cell cycle arrest and apoptosis in cancer cells.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Ma Fei，MD portfolio CI brief
• Ma Fei，MD pipeline updates RSS